NewsRoom Articles - Page 7 of 213

ThursdayJul 03, 2025 10:00 am

Study Discovers Genetic Mutation that Makes Solid Tumors Unresponsive to Immunotherapy

While studying why non-human primates aren’t as likely to suffer from certain cancers when compared to humans, UC Davis scientists discovered a genetic mutation that could explain this anomaly. Their findings were published in the Nature Communications journal. This discovery could open the door to the development of more powerful treatments for cancer. The researchers focused on Fas Ligand, an immune protein that helps in attacking tumor cells. This protein is present in both human and non-human primates like chimpanzees. The scientists discovered that in humans, a small mutation makes FasL to be easily deactivated by a tumor-linked enzyme called…

WednesdayJul 02, 2025 9:45 am

Adageis: An AI-Powered Advocate for Healthcare Providers

Adageis, a company offering a powerful and patented AI-centric software solution, remains committed to streamlining the healthcare sector, making it easier for providers to meet their financial goals It works with over 90 Electronic Health Record platforms, an unrivalled level of access that gives its users actionable insights at the point of care The company covers over 260,000 patient lives, and looks to double that to 580,000, achieving its $100,000 monthly recurring revenue target Adageis, a company offering powerful and patented AI-based software, provides flexible healthcare and related software solutions for providers and healthcare systems. The company remains committed to…

WednesdayJul 02, 2025 9:00 am

Soligenix Inc. (NASDAQ: SNGX) Highlights Encouraging Phase 3 Progress for HyBryte(TM) in Investment Webinar

A focus during the webinar was the investigator-initiated study currently being conducted at the University of Pennsylvania under the leadership of Dr. Ellen Kim. Interim results show that among the first eight patients who completed 18 weeks of treatment, 75% demonstrated a greater than 50% reduction in disease severity. Soligenix anticipates top-line results from the phase 3 trial in the second half of 2026. In a recent webinar hosted by Allele Capital, Soligenix (NASDAQ: SNGX) executives Dr. Christopher Schaber and Dr. Christopher Pullion shared detailed updates on the company’s HyBryte(TM) (synthetic hypericin) clinical development (https://ibn.fm/dz7eO). The event offered an in-depth look at…

TuesdayJul 01, 2025 10:00 am

Research Finds That Pesticides Disrupt Inflammation-Linked Bacteria

Existing scientific information shows that pesticides are toxic to the microorganisms in the gut, and a new preclinical study has mapped the specific impacts that compounds in pesticides have on microbes in the human digestive system. One surprising finding emerged regarding how these pesticide compounds affect the inflammatory system in the body. The Ohio State University team of researchers conducted an analysis aimed at establishing the specific ways in which different active ingredients in pesticides impact the ways in which bacteria in the gut grow and how the affected bacteria alter the ways in which nutrients are processed in the…

FridayJun 27, 2025 10:00 am

Research Links Key Proteins to the Growth of Brain Tumors

University of Plymouth researchers in the UK have identified the proteins that underlie the growth and development of common brain tumors. Their findings could, in the long run, trigger the development of new treatments which are less invasive. Through investigations undertaken at labs at the Plymouth Science Park, PhD students, together with other scientists studied the molecular subtypes of tumors called meningiomas. They found that ANXA3, a type of protein, was a key driver behind the growth of some meningioma cells. By inhibiting the functioning of these proteins, the team was able to slow down, and in some instances, altogether…

FridayJun 27, 2025 9:45 am

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Applies for FDA Commissioner’s National Priority Voucher for IV Ketamine NRX-100

The new FDA voucher program aims to speed approval of drugs aligned with national health priorities. NRX-100, a preservative-free ketamine, is also under an Abbreviated New Drug Application (“ANDA”) with a priority review request. NRx has submitted full CMC data and draft labeling for NRX-100, meeting key Commissioner’s National Priority Voucher pre-qualification criteria. The company’s U.S.-based manufacturing aims to reduce foreign supply chain dependence and address diversion concerns. A patent on the preservative-free process and a citizen petition to withdraw preserved ketamine could bolster NRx’s market position. NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company developing innovative treatments for suicidal depression and…

ThursdayJun 26, 2025 10:00 am

Why Public Interest in Mitochondrial Function Testing is Growing

Today, more ordinary people are taking an interest in tracking their mitochondrial health in order to take concrete steps to improve their overall wellness and boost longevity. Previously, such interest was a mainstay among elite athletes, scientists and biohacking enthusiasts. Why are more people choosing to have their mitochondrial health tested? For starters, mitochondria are powerhouses inside body cells. These organelles play several vital roles, such as generating energy for cellular use, participating in the immune system’s response to pathogens, contributing to cell signaling, and playing a role in programmed cell death (aka apoptosis). Mitochondrial health is therefore essential to…

ThursdayJun 26, 2025 9:45 am

Lantern Pharma Inc.’s (NASDAQ: LTRN) AI-Powered Platform Delivers Promising and Durable Results in Lung Cancer Trial

Lantern Pharma uses a proprietary AI platform, RADR®, to guide its oncology drug development, enabling rapid drug candidate identification and targeted trial design based on genomic and biomarker data. A Phase 2 trial patient achieved a complete response in their primary cancer lesions after multiple prior therapies failed and has remained responsive to LP-300 for two years signaling durable clinical benefit in this challenging population. The target population, never-smokers with non-small cell lung cancer, represents a growing global unmet need estimated at over $4 billion annually. Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotechnology company leveraging artificial intelligence and machine learning…

TuesdayJun 24, 2025 10:00 am

Could Wheat Germ Hold the Key to Supercharging Immunotherapy? New Research Hopes to Find Out

An ongoing clinical trial at the Comprehensive Cancer Center at UC Davis seeks to find out whether fermented wheat germ could help cancer patients undergoing immunotherapy have better outcomes and live full lives, or even beat cancer. This pioneering study is being conducted by Joseph Tuscano, an oncologist specializing in blood cancers like multiple myeloma, leukemia and lymphoma. This research is being funded by the family of a patient who succumbed to cancer but had previously shown remarkable improvement after using fermented wheat germ to supplement his immunotherapy. The Veterans Administration is also funding the study. The use of fermented…

FridayJun 20, 2025 10:00 am

How Robotics Technology is Transforming Healthcare

Robotics is playing an ever-increasing role in revolutionizing healthcare. The medical industry is playing a leading role in the adoption of robotics and the pace at which these technologies are being adopted is accelerating. It is therefore not surprising that the market for medical robotics is forecast to grow from $16.6bn to $63.8bn between 2023 and 2032. Several applications of these technologies are justifying further deployment. Speeding up diagnosis Intuitive, a U.S. firm, developed a robotic-assisted system and platform called Ion. This tool and the supporting system is geared at conducting bronchoscopies in a minimally invasive way in order to…